Subgroup effects despite homogeneous heterogeneity test resultsRolf H H Groenwold
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
BMC Med Res Methodol 10:43. 2010
..Lack of demonstrable statistical heterogeneity, however, might obscure clinical heterogeneity, meaning clinically relevant subgroup effects...
- Blood pressure reduction in stable angina by nifedipine was related to stroke and heart failure reduction but not to coronary interventions
Jacobus Lubsen
SOCAR Research, PO Box 2564, CH 1260 Nyon, Switzerland
J Clin Epidemiol 60:720-6. 2007
..Whether blood pressure (BP) reduction is a necessary prerequisite for cardiovascular risk reduction or an epiphenomenon has not been definitively established. We used an innovative analytic method to address this question...
- Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial
Jacobus Lubsen
SOCAR Research SA, Nyon, Switzerland
J Hypertens 23:641-8. 2005
..To examine the effects of nifedipine GITS on clinical outcome in patients with concurrent stable angina and hypertension...
- Epidemiology: indeed "quo vadis"?
Jacobus Lubsen
Department of Epidemiology and Biostatistics, Erasmus Medical Centre, Rotterdam, The Netherlands
Eur J Epidemiol 19:749-50. 2004
- Combined endpoints: can we use them?
Jacobus Lubsen
SOCAR Research SA, Nyon, Switzerland
Stat Med 21:2959-70. 2002
....
- Quality management of a large randomized double-blind multi-centre trial: the ACTION experience
Bridget Anne Kirwan
SOCAR Research, PO Box 2564, CH 1260 Nyon, Switzerland
Contemp Clin Trials 29:259-69. 2008
..Unequivocal operational definitions of the procedural concepts that characterize randomized clinical trials should not only be the basis of QM, but also of reporting results...
- Diagnostic criteria and adjudication process both determine published event-rates: the ACTION trial experience
Bridget Anne Kirwan
SOCAR Research, PO Box 2564, CH 1260 Nyon, Switzerland
Contemp Clin Trials 28:720-9. 2007
..The final diagnosis was always made by a critical events committee (CEC) using standard criteria...
- Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial
Philip A Poole-Wilson
Cardiac Medicine, Imperial College London, Dovehouse Street, London SW3 6LY, UK
Lancet 364:849-57. 2004
..We aimed to investigate the effect of the calcium antagonist nifedipine on long-term outcome in patients with stable angina pectoris...
- Predictive value of local and core laboratory echocardiographic assessment of cardiac function in patients with chronic stable angina: The ACTION study
Anthony M Dart
Cardiovascular Medicine, Alfred Hospital, Melbourne, Victoria, Australia
Eur J Echocardiogr 8:275-83. 2007
..To evaluate the relationship between echocardiographic cardiac function and outcome in patients with stable symptomatic angina...
- Resource utilization implications of treatment were able to be assessed from appropriately reported clinical trial data
Philip A Poole Wilson
Cardiac Medicine, Imperial College, Dovehouse Street, London SW3 6LY, UK
J Clin Epidemiol 60:727-33. 2007
..Published clinical trial data rarely allow assessment of the health care resource utilization implications of treatment. We give an example of how these can be assessed given appropriate tabulation of data...
- Incidence and outcome of atrial fibrillation in stable symptomatic coronary disease
Jan Erik Otterstad
Hospital of Vestfold, Toensberg, Norway
Scand Cardiovasc J 40:152-9. 2006
..Evaluate the prevalence, incidence and impact on prognosis of existing and new onset atrial fibrillation (AF) in patients with stable, symptomatic coronary artery disease...
- A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET)
John G F Cleland
Department of Cardiology, University of Hull, Kingston upon Hull, United Kingdom
J Am Coll Cardiol 47:1603-11. 2006
..This study was designed to investigate the loss of well-being, in terms of life-years, overall and in patients randomized to metoprolol versus carvedilol in the Carvedilol Or Metoprolol European Trial (COMET)...
- Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients
Tim C Clayton
Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT
BMJ 331:869. 2005
..CONCLUSION: This risk score is an objective aid in deciding on further management of patients with stable angina with the aim of reducing serious outcome events. The score can also be used in planning future trials...
- A propensity-matched study of hypertension and increased stroke-related hospitalization in chronic heart failure
Gerasimos S Filippatos
University of Athens, Athens, Greece
Am J Cardiol 101:1772-6. 2008
..81; p=0.044). In conclusion, a history of hypertension was associated with increased risk of hospitalization for stroke among patients with heart failure who were balanced in all measured baseline covariates, including blood pressure...
- Safety of nifedipine GITS in stable angina: the ACTION trial
Philip A Poole-Wilson
Department of Cardiac Medicine, Imperial College, London, UK
Cardiovasc Drugs Ther 20:45-54. 2006
..53/100 patient years for patients assigned nifedipine and 2.37/100 patient years for patients assigned placebo (HR 1.06, 95% CI 0.93-1.22). CONCLUSION: Overall nifedipine GITS was well tolerated by patients with stable symptomatic angina...
- Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome
Luis M Ruilope
Hypertension Unit, Hospital 12 de Octubre Madrid, Spain
J Hypertens 25:1711-8. 2007
..Little data is available concerning the prognostic implications of renal function abnormalities, their evolution over time and the effects of nifedipine on such abnormalities in patients with stable angina pectoris...
- Clinical course of isolated stable angina due to coronary heart disease
Philip A Poole-Wilson
Cardiac Medicine, National Heart and Lung Institute, Imperial College London, London, UK
Eur Heart J 28:1928-35. 2007
..To describe the clinical course of patients with stable angina due to coronary heart disease without a history of cardiovascular (CV) events or revascularization (isolated angina)...
- Variable impact of combining fatal and nonfatal end points in heart failure trials
Hicham Skali
Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA
Circulation 114:2298-303. 2006
..Longer-duration trials have a more predictable increase in events than short RCTs. Trial duration must be considered when composite end points are used during the design and interpretation of HF RCTs...
- The development of heart failure in patients with stable angina pectoris
George C Sutton
Cardiac Medicine, National Heart and Lung Institute, Imperial College London, London, UK
Eur J Heart Fail 9:234-42. 2007
..To describe the clinical characteristics of patients with stable angina pectoris who develop heart failure and the events preceding its onset...
- Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
Philip A Poole-Wilson
National Heart and Lung Institute, Imperial College, London, UK
Lancet 362:7-13. 2003
..We aimed to compare the effects of carvedilol and metoprolol on clinical outcome...
- Outcome following percutaneous transluminal coronary angioplasty performed before 1990
Samuel F Mpyisi
Division of Cardiology, Center Hospitalier Universitaire Vaudois (CHUV, Rue du Bugnon 17, 1011 Lausanne, Switzerland
J Interv Cardiol 15:355-61. 2002
..The short-term observations are consistent with results reported by the other follow-up studies. In addition, the study found a total survival rate 14 years after a first PTCA of 69% and 47% of the cohort remained event free...
- Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study
Philip A Poole-Wilson
Lancet 359:2199; author reply 2203-4. 2002
